GSK Extends Product Portfolio In Middle East, North Africa
Business comprises a portfolio of 13 branded pharmaceuticals
GlaxoSmithKline (GSK) has acquired the branded generics business of Bristol Myers Squibb in Lebanon, Jordan, Syria, Libya and Yemen for $23.2 million. The business comprises a portfolio of 13 branded pharmaceuticals.
The company said that this is a strategy to accelerate growth in emerging markets and to provide medicines to patients in the Middle East and North Africa.
The acquisition builds upon GSK’s previous purchases of mature branded products in 2008 from Bristol Myers Squibb in Pakistan and Egypt, which included a manufacturing plant in Giza, Greater Cairo. Bristol Myers Squibb will continue to supply the products acquired until 2011, when it is anticipated that manufacture will transfer to GSK’s Giza plant.
Related Insight
Suppliers Directory
NDA - Regulatory Affairs and Development Consultancy Partner
NDA is the pharmaceutical industry's leading European regulatory affairs and development consultancy partner, as confirmed by the unsurpassed success history in recent European regulatory accomplishments. In 2009 NDA advised on 33% of all products approved centrally in the EU.
Suppliers
Haselmeier - Self-Injection Devices
Haselmeier is dedicated to meeting the self-injection needs of pharmaceutical manufacturers and patients.
Suppliers
Finesse Solutions - Measurement and Control Technologies
California-based Finesse Solutions, LLC, leads the way in developing new measurement and control technologies, in order to enable the transition to single-use systems, bring new capabilities to existing bioreactor platforms, and harmonise global bio-process information transfer.
Suppliers
NEUROFIT - Preclinical Research
NEUROFIT is a CRO (Contract Research Organisation) specialised in the evaluation of treatments for central (CNS) and peripheral nervous system (PNS) disorders, autoimmune diseases and for Oncology.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Plastic Volumetric Flasks and Reagent Bottles Now Also With Light Protection
Published by VITLAB®
White Papers
Digital ECG
Published by CoreLab Partners
White Papers
Basic Principles of Dry Granulation and Roller Compaction Technology
Published by Gerteis
White Papers
SHL Medical Product Overview
Published by SHL Group (Scandinavian Health Group Ltd.)
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.